TuisAZN • LON
add
AstraZeneca plc
Vorige sluiting
GBX 13 750,00
Dagwisseling
GBX 13 722,00 - GBX 13 844,00
Jaarwisseling
GBX 9 573,50 - GBX 15 474,36
Markkapitalisasie
285,33 mjd USD
Gemiddelde volume
2,20 m
P/V-verhouding
30,85
Dividend-opbrengs
1,77%
Primêre beurs
LON
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 15,19 mjd | 11,99% |
Bedryfskoste | 8,74 mjd | 4,29% |
Netto inkomste | 2,53 mjd | 77,26% |
Netto winsgrens | 16,67 | 58,31% |
Wins per aandeel | 2,38 | 128,85% |
EBITDA | 5,21 mjd | 32,83% |
Effektiewe belastingkoers | 21,86% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 8,18 mjd | 65,96% |
Totale bates | 114,46 mjd | 9,09% |
Totale aanspreeklikheid | 68,48 mjd | 6,81% |
Totale ekwiteit | 45,97 mjd | — |
Uitstaande aandele | 1,55 mjd | — |
Prys om te bespreek | 4,65 | — |
Opbrengs op bates | 8,07% | — |
Opbrengs op kapitaal | 11,71% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,53 mjd | 77,26% |
Kontant van bedrywe | 5,13 mjd | 51,76% |
Kontant van beleggings | -2,00 mjd | -32,17% |
Kontant van finansiering | -2,07 mjd | 49,82% |
Netto kontantverandering | 1,05 mjd | 146,74% |
Beskikbare kontantvloei | 2,80 mjd | 56,04% |
Meer oor
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Gestig
06 Apr. 1999
Hoofkwartier
Webwerf
Werknemers
94 300